This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bernstein Liebhard LLP Investigating Anatabloc Lawsuit Claims Against Manufacturers And Sellers Of Dietary Supplement Purported To Treat Chronic And Incurable Medical Conditions

NEW YORK, Feb. 6, 2014 /PRNewswire/ -- The nationwide law firm of Bernstein Liebhard LLP is now investigating Anatabloc lawsuit ( claims against Star Scientific Inc. (NASDAQ: STSI), Rock Creek Pharmaceuticals, Inc. and GNC Holdings, Inc. (NYSE: GNC), the manufacturers and sellers of Anatabloc dietary supplements. Anatabloc was recently the subject of a warning letter issued by the U.S. Food & Drug Administration (FDA) that asserted claims regarding the ability of anatabine, a key ingredient the product, to treat certain chronic and incurable medical conditions were unfounded.

(Logo: )

"Our Firm is eager to hear from any consumer who purchased Anatabloc dietary supplements. The allegedly misleading statements used by Star Scientific  to promote the sale of this product may entitle those consumers to a refund of the purchase price, as well as other damages," says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to individuals who are interested in filing an Anatabloc lawsuit.

Anatabloc FDA Warning Letter

Anatabloc is manufactured by Star Scientific, a wholly-owned subsidiary of Rock Creek Pharmaceuticals, Inc. The product retails for $99.00 per bottle, and is available for sale at GNC, a nationwide chain of health and wellness stores.  A key ingredient in Anatabloc is anatabine, which occurs naturally in cauliflower, eggplant, potatoes, and tomatoes,

On December 20, 2013, the FDA issued a warning letter to Star Scientific which took issue with statements made by the company regarding anatabine's anti-inflammatory properties, specifically its purported ability to mitigate inflammatory bowel disease, ulcerative colitis, Crohn's disease and traumatic brain injury. The FDA warning letter also characterized anatabine as a new drug that requires approval by the FDA.

On December 31, the FDA released a Consumer Alert that specifically noted the warning letter issued to Star Scientific. The purpose of the Alert was to caution the public about companies which offer untested, unproven and possibly dangerous products that claim to prevent, treat or cure concussions and other traumatic brain injuries. According to the agency, these products are not backed by scientific evidence that proves they are safe or effective for such purposes.

Consumers who purchased Anatabloc dietary supplements may be entitled to compensation from the manufacturers and sellers of this product. To learn more about filing an Anatabloc lawsuit, please visit Bernstein Liebhard LLP's website. To obtain a free review of your case, please call (888) 340-4807.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.02 0.00%
FB $104.07 0.00%
GOOG $683.57 0.00%
TSLA $162.60 0.00%
YHOO $27.97 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs